Nanoparticles in the clinic: An update
Tóm tắt
Nanoparticle drug delivery systems have been used in the clinic since the early 1990's. Since that time, the field of nanomedicine has evolved alongside growing technological needs to improve the delivery of various therapeutics. Over these past decades, newer generations of nanoparticles have emerged that are capable of performing additional delivery functions that can enable treatment via new therapeutic modalities. In the current clinical landscape, many of these new generation nanoparticles have reached clinical trials and have been approved for various indications. In the first issue of
Từ khóa
Tài liệu tham khảo
FDA News Release. FDA approves first treatment for certain types of poor‐prognosis acute myeloid leukemia.2017.http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia. Accessed August 3 2019.
VYXEOS™ Prescription Drug Labeling.2017.http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf. Accessed August 3 2019.
Banerjee K, 2017, CPX‐351 exposure‐response based on cumulative dose of cytarabine and daunorubicin in patients with newly diagnosed, treatment‐related acute myeloid leukemia (AML) or AML with myelodysplasia‐related changes, Am Soc Hematology, 130, 1360
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results.2019.https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-full-year-and-fourth-quarter-2018. Accessed August 20 2019.
Mullard A, 2018, FDA approves landmark RNAi drug, Nat Rev Drug Discov, 17, 613, 10.1038/nrd.2018.152
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity.2019.http://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-reports-fourth-quarter-and-full-year-6. Accessed August 3 2019.
Nanobiotix Press Release. Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval.2019.http://www.nanobiotix.com/download/news_en/2019/PR_Nanobiotix_marquage_CE_04042019_VF.pdf. Accessed August 3 2019.
Hu Y, 2019, Abstract 3225: enhancement of anti‐PD1 and anti‐CTLA4 efficacy by NBTXR3 nanoparticles exposed to radiotherapy, Cancer Res, 79, 3225, 10.1158/1538-7445.AM2019-3225
Rodriguez‐Ruiz ME, 2019, Abstract 536: NBTXR3 potentiate cancer‐cell intrinsic interferon beta response to radiotherapy, Cancer Res, 79, 536, 10.1158/1538-7445.AM2019-536
Merrimack Press Release. Merrimack Stops the Phase 2 HERMIONE Trial of MM‐302 in HER2‐Positive Metastatic Breast Cancer Patients.2016.http://investors.merrimack.com/news-releases/news-release-details/merrimack-stops-phase-2-hermione-trial-mm-302-her2-positive. Accessed August 3 2019.
Dicerna Press Release. Dicerna Prioritizes Resources to Advance GalXC™ Product Candidates.2016.http://investors.dicerna.com/news-releases/news-release-details/dicerna-prioritizes-resources-advance-galxctm-product-candidates. Accessed August 3 2019.
BIND Therapeutics Press Release. BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets.2016https://www.pfizer.com/sites/default/files/partnering/recent_partnership/BIND-winning-bid-release-072616-FINAL.pdf. Accessed August 3 2019.